LDS/Medical Tests/Dextromethorphan, Urine

Dextromethorphan, Urine

Dextromethorphan (DXM) is a cough suppressor (antitussive) found in more than 120 over-the-counter cold medications, either alone or in combination with analgesics, antihistamines, decongestants, and/or expectorants. A typical adult dose is 15 or 30 mg taken several times a day, with a maximum of 120 mg a day. The typical effects of a dose of DXM last approximately 5-6 hours. DXM is one of the abused drugs in the category of "amphetamines" since it is a primary amine itself. In high doses DXM will produce euphoria and visual and auditory hallucinations. DXM abuse has traditionally involved drinking large volumes of the over-the-counter liquid preparations. More recently, however, abuse of tablet and gel capsule preparations has increased. DXM is also distributed in illicitly manufactured tablets containing only DXM or mixed with other drugs such as pseudoephedrine and/or methamphetamine.

The effects associated with DXM abuse include confusion, agitation, paranoia, and hallucinations. Approximately 5-10% of Caucasians are poor DXM metabolizers and at risk for overdoses and deaths. DXM taken with antidepressants can be life threatening. Depending on the dose DXM can mimic the effects of marijuana or Ecstasy.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay (IA) test indicates only the presence of primary amines and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS

Therapeutic concentration: 2-6 ng/mL (higher in poor metabolizers)

Toxic concentration: >40 ng/mL

Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.

 

Cut-Off Ranges

Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, whether it is a qualitative method such as IA, or a quantitative method such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect DXM. DXM can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step is often used to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Urine

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 hours
  • Refrigeration: 14 days
  • Frozen: 14 days
DXM is a substrate of many of the CYP450 family of enzymes. Therefore, pharmacogenetic testing such as genotyping for *CYP2D6, CYP3A4, CYP2C9, CYP2C19, and CYP2B6* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Dextromethorphan DEA Drug Fact Sheet
  • Levine B (ed). Amphetamines/Sympathomimetic Amines. In: Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press; 2013: 353-371.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.